1
|
Nemati F, Ata Bahmani Asl A, Salehi P. Synthesis and modification of noscapine derivatives as promising future anticancer agents. Bioorg Chem 2024; 153:107831. [PMID: 39321713 DOI: 10.1016/j.bioorg.2024.107831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2024] [Revised: 09/15/2024] [Accepted: 09/16/2024] [Indexed: 09/27/2024]
Abstract
Noscapine, a tetrahydroisoquinoline alkaloid, was first isolated from Papaver somniferum and identified by Rabiquet in 1817. It has been used as an anti-tussive agent since the mid-1950 s. After the discovery of its anti-mitotic potential, it was into the limelight once again. Due to its low toxicity, high bioactivity and oral administration, It was regarded as a formidable framework for subsequent modification and advancement in the pursuit of innovative chemotherapeutic agents. Up to now, the rational derivatives of the noscapine have been designed and the biological activities of these analogues have been extensively investigated. This review provides a comprehensive examination of the chemical characteristics of noscapine and its semi-synthetic derivatives up to the present, encompassing a concise investigation into the biological properties of these compounds and additionally a discussion about biosynthesis and total synthesis of noscapine is also provided. In summary, our aim is to contribute to a more thorough comprehension of this structure. It can be asserted that a promising future lies ahead for noscapine and its engineered derivatives as noteworthy candidates for pharmaceutical drugs.
Collapse
Affiliation(s)
- Faezeh Nemati
- Department of Synthesis of Medicinal Organic Compounds, Institute of Medicinal Chemistry, Iranian Research Organization for Science and Technology (IROST), P.O. Box 33535111, Tehran, Iran
| | - Amir Ata Bahmani Asl
- Department of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Evin, 1983963113 Tehran, Iran
| | - Peyman Salehi
- Department of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Evin, 1983963113 Tehran, Iran.
| |
Collapse
|
2
|
Meher RK, Mir SA, Anisetti SS. In silico and in vitro investigation of dual targeting Prima-1 MET as precision therapeutic against lungs cancer. J Biomol Struct Dyn 2024; 42:4169-4184. [PMID: 37272907 DOI: 10.1080/07391102.2023.2219323] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Accepted: 05/23/2023] [Indexed: 06/06/2023]
Abstract
This study emphasizes the explorations of binding of Prima-1MET with two targets, p53 a tumor suppressor protein, and tyrosine kinase of epidermal growth factor receptor. In silico investigations reveal that Prima-1MET showed robust binding with both targets. Molecular docking simulations demonstrated the binding affinity of Prima-1MET with p53 and tyrosine kinase was found to be -38.601 kJ/mol and -38.976 kJ/mol. In addition, the stability of Prima-1MET was explored by molecular dynamics simulation. Prima-1MET attains stability in the binding site of the respective protein till the simulation period is over. Moreover, the free binding energy ΔGbind was calculated by the molecular mechanics Poisson Boltzmann surface area method. The ΔGbind of Prima-1MET with tyrosine kinase was found to be -58.585 ± 0.327 kJ/mol and with p53 it was -35.910 ± 0.335 kJ/mol. Next, cytotoxicity of the Prima-1MET was evaluated using multiple cancer cell lines and the IC50 value were ranging between 4.5 and 30 μM. The cell death was identified by apoptosis assay. Further, the p53 and tyrosine kinase expression was monitored using immunofluorescence techniques, it was found Prima-1MET induces the expression of p53 protein and mimics the level of tyrosine kinase oncogenic target. Also, reactive oxygen species (ROS) and membrane potential activity of Prima-1MET was evaluated by using a lung cancer cell line. A significant decrease in intracellular ROS was observed and resulted in disruption of mitochondrial transmembrane potential. This study uncovers the underlying mechanism of Prima-1MET and could be helpful to design further leads against lung cancers.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Rajesh Kumar Meher
- Advance Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Mumbai, India
- Department of Biotechnology and Bioinformatics, Sambalpur University, Burla, Odisha, India
| | | | | |
Collapse
|
3
|
Computational Approaches to the Rational Design of Tubulin-Targeting Agents. Biomolecules 2023; 13:biom13020285. [PMID: 36830654 PMCID: PMC9952983 DOI: 10.3390/biom13020285] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 01/27/2023] [Accepted: 01/31/2023] [Indexed: 02/05/2023] Open
Abstract
Microtubules are highly dynamic polymers of α,β-tubulin dimers which play an essential role in numerous cellular processes such as cell proliferation and intracellular transport, making them an attractive target for cancer and neurodegeneration research. To date, a large number of known tubulin binders were derived from natural products, while only one was developed by rational structure-based drug design. Several of these tubulin binders show promising in vitro profiles while presenting unacceptable off-target effects when tested in patients. Therefore, there is a continuing demand for the discovery of safer and more efficient tubulin-targeting agents. Since tubulin structural data is readily available, the employment of computer-aided design techniques can be a key element to focus on the relevant chemical space and guide the design process. Due to the high diversity and quantity of structural data available, we compiled here a guide to the accessible tubulin-ligand structures. Furthermore, we review different ligand and structure-based methods recently used for the successful selection and design of new tubulin-targeting agents.
Collapse
|
4
|
Zhang D, Wu F, Wan Z, Wang Y, He X, Guo B, You H, Chen FE. A palladium polyaniline complex: a simple and efficient catalyst for batch and flow Suzuki-Miyaura cross-couplings. Chem Commun (Camb) 2022; 58:10845-10848. [PMID: 36073300 DOI: 10.1039/d2cc04051d] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
A novel palladium polyaniline complex (Pd@PANI) was synthesized via a one-pot method using a low concentration of hydrogen peroxide (3 wt%) as a mild oxidant. Pd@PANI was employed to catalyze Suzuki-Miyaura cross-couplings with 0.11 ppm levels of palladium and high turnover numbers (up to 6.1 × 104). Various aromatic halides and aromatic boric acids were used as reaction partners to prepare the biaryl compounds in high yields. Application of the method in the synthesis of D-fructose derivatives was also performed. Furthermore, the catalyst was evaluated under a flow process to provide the corresponding products in good yields with shorter residence times and lower temperatures in more convenient operations compared with the batch conditions.
Collapse
Affiliation(s)
- Dongliang Zhang
- School of Science, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China. .,Green Pharmaceutical Engineering Research Center, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China
| | - Fusong Wu
- School of Science, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China. .,Green Pharmaceutical Engineering Research Center, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China
| | - Zhijian Wan
- School of Science, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China.
| | - Yichun Wang
- School of Science, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China.
| | - Xuan He
- School of Science, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China.
| | - Bing Guo
- School of Science, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China.
| | - Hengzhi You
- School of Science, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China. .,Green Pharmaceutical Engineering Research Center, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China
| | - Fen-Er Chen
- School of Science, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China. .,Green Pharmaceutical Engineering Research Center, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China.,Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai, 200433, China
| |
Collapse
|